Trubion Pharmaceuticals (TRBN) Up Over 60%
August 28, 2009 · Filed Under R&D
Trubion Pharmaceuticals (TRBN) is up 63% to $6.43, a 52-week high. The move may be a little much for the microcap.
The company and Facet Biotech (FACT) announced an agreement for the joint worldwide development and commercialization of TRU-016, a product candidate in phase 1 clinical development for chronic lymphocytic leukemia (CLL).
Not very substantial news for such a big run
Douglas A. McIntyre
